Trials / Completed
CompletedNCT02194933
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity
Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of brexpiprazole, via functional magnetic resonance imaging (fMRI), on the right ventrolateral prefrontal cortex (VLPFC) activated by impulsive behavior.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brexpiprazole | Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks |
Timeline
- Start date
- 2015-02-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-07-21
- Last updated
- 2018-11-08
- Results posted
- 2018-09-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02194933. Inclusion in this directory is not an endorsement.